A new cell-penetrating peptide that blocks the autoinhibitory XIP domain of NCX1 and enhances antiporter activity

Pasquale Molinaro, Anna Pannaccione, Maria José Sisalli, Agnese Secondo, Ornella Cuomo, Rossana Sirabella, Maria Cantile, Roselia Ciccone, Antonella Scorziello, Gianfranco Di Renzo, Lucio Annunziato

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The plasma membrane Na+/Ca2+ exchanger (NCX) is a high-capacity ionic transporter that exchanges 3Na+ ions for 1Ca2+ ion. The first 20 amino acids of the f-loop, named exchanger inhibitory peptide (XIPNCX1), represent an autoinhibitory region involved in the Na+-dependent inactivation of the exchanger. Previous research has shown that an exogenous peptide having the same amino acid sequence as the XIPNCX1 region exerts an inhibitory effect on NCX activity. In this study, we identified another regulatory peptide, named P1, which corresponds to the 562-688aa region of the exchanger. Patch-clamp analysis revealed that P1 increased the activity of the exchanger, whereas the XIP inhibited it. Furthermore, P1 colocalized with NCX1 thus suggesting a direct binding interaction. In addition, site-directed mutagenesis experiments revealed that the binding and the stimulatory effect of P1 requires a functional XIPNCX1 domain on NCX1 thereby suggesting that P1 increases the exchanger activity by counteracting the action of this autoinhibitory sequence. Taken together, these results open a new strategy for developing peptidomimetic compounds that, by mimicking the functional pharmacophore of P1, might increase NCX1 activity and thus exert a therapeutic action in those diseases in which an increase in NCX1 activity might be helpful.

Original languageEnglish
Pages (from-to)465-476
Number of pages12
JournalMolecular Therapy
Volume23
Issue number3
DOIs
Publication statusPublished - Mar 5 2015

Fingerprint

Cell-Penetrating Peptides
Antiporters
Peptidomimetics
Peptides
Ion Exchange
Site-Directed Mutagenesis
Amino Acid Sequence
Cell Membrane
Ions
Amino Acids
Research
Therapeutics
exchanger inhibitory peptide

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Genetics
  • Drug Discovery
  • Pharmacology

Cite this

A new cell-penetrating peptide that blocks the autoinhibitory XIP domain of NCX1 and enhances antiporter activity. / Molinaro, Pasquale; Pannaccione, Anna; Sisalli, Maria José; Secondo, Agnese; Cuomo, Ornella; Sirabella, Rossana; Cantile, Maria; Ciccone, Roselia; Scorziello, Antonella; Di Renzo, Gianfranco; Annunziato, Lucio.

In: Molecular Therapy, Vol. 23, No. 3, 05.03.2015, p. 465-476.

Research output: Contribution to journalArticle

Molinaro, P, Pannaccione, A, Sisalli, MJ, Secondo, A, Cuomo, O, Sirabella, R, Cantile, M, Ciccone, R, Scorziello, A, Di Renzo, G & Annunziato, L 2015, 'A new cell-penetrating peptide that blocks the autoinhibitory XIP domain of NCX1 and enhances antiporter activity', Molecular Therapy, vol. 23, no. 3, pp. 465-476. https://doi.org/10.1038/mt.2014.231
Molinaro, Pasquale ; Pannaccione, Anna ; Sisalli, Maria José ; Secondo, Agnese ; Cuomo, Ornella ; Sirabella, Rossana ; Cantile, Maria ; Ciccone, Roselia ; Scorziello, Antonella ; Di Renzo, Gianfranco ; Annunziato, Lucio. / A new cell-penetrating peptide that blocks the autoinhibitory XIP domain of NCX1 and enhances antiporter activity. In: Molecular Therapy. 2015 ; Vol. 23, No. 3. pp. 465-476.
@article{ffeeb9f93dd84de89d26c5f6a119fbc3,
title = "A new cell-penetrating peptide that blocks the autoinhibitory XIP domain of NCX1 and enhances antiporter activity",
abstract = "The plasma membrane Na+/Ca2+ exchanger (NCX) is a high-capacity ionic transporter that exchanges 3Na+ ions for 1Ca2+ ion. The first 20 amino acids of the f-loop, named exchanger inhibitory peptide (XIPNCX1), represent an autoinhibitory region involved in the Na+-dependent inactivation of the exchanger. Previous research has shown that an exogenous peptide having the same amino acid sequence as the XIPNCX1 region exerts an inhibitory effect on NCX activity. In this study, we identified another regulatory peptide, named P1, which corresponds to the 562-688aa region of the exchanger. Patch-clamp analysis revealed that P1 increased the activity of the exchanger, whereas the XIP inhibited it. Furthermore, P1 colocalized with NCX1 thus suggesting a direct binding interaction. In addition, site-directed mutagenesis experiments revealed that the binding and the stimulatory effect of P1 requires a functional XIPNCX1 domain on NCX1 thereby suggesting that P1 increases the exchanger activity by counteracting the action of this autoinhibitory sequence. Taken together, these results open a new strategy for developing peptidomimetic compounds that, by mimicking the functional pharmacophore of P1, might increase NCX1 activity and thus exert a therapeutic action in those diseases in which an increase in NCX1 activity might be helpful.",
author = "Pasquale Molinaro and Anna Pannaccione and Sisalli, {Maria Jos{\'e}} and Agnese Secondo and Ornella Cuomo and Rossana Sirabella and Maria Cantile and Roselia Ciccone and Antonella Scorziello and {Di Renzo}, Gianfranco and Lucio Annunziato",
year = "2015",
month = "3",
day = "5",
doi = "10.1038/mt.2014.231",
language = "English",
volume = "23",
pages = "465--476",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - A new cell-penetrating peptide that blocks the autoinhibitory XIP domain of NCX1 and enhances antiporter activity

AU - Molinaro, Pasquale

AU - Pannaccione, Anna

AU - Sisalli, Maria José

AU - Secondo, Agnese

AU - Cuomo, Ornella

AU - Sirabella, Rossana

AU - Cantile, Maria

AU - Ciccone, Roselia

AU - Scorziello, Antonella

AU - Di Renzo, Gianfranco

AU - Annunziato, Lucio

PY - 2015/3/5

Y1 - 2015/3/5

N2 - The plasma membrane Na+/Ca2+ exchanger (NCX) is a high-capacity ionic transporter that exchanges 3Na+ ions for 1Ca2+ ion. The first 20 amino acids of the f-loop, named exchanger inhibitory peptide (XIPNCX1), represent an autoinhibitory region involved in the Na+-dependent inactivation of the exchanger. Previous research has shown that an exogenous peptide having the same amino acid sequence as the XIPNCX1 region exerts an inhibitory effect on NCX activity. In this study, we identified another regulatory peptide, named P1, which corresponds to the 562-688aa region of the exchanger. Patch-clamp analysis revealed that P1 increased the activity of the exchanger, whereas the XIP inhibited it. Furthermore, P1 colocalized with NCX1 thus suggesting a direct binding interaction. In addition, site-directed mutagenesis experiments revealed that the binding and the stimulatory effect of P1 requires a functional XIPNCX1 domain on NCX1 thereby suggesting that P1 increases the exchanger activity by counteracting the action of this autoinhibitory sequence. Taken together, these results open a new strategy for developing peptidomimetic compounds that, by mimicking the functional pharmacophore of P1, might increase NCX1 activity and thus exert a therapeutic action in those diseases in which an increase in NCX1 activity might be helpful.

AB - The plasma membrane Na+/Ca2+ exchanger (NCX) is a high-capacity ionic transporter that exchanges 3Na+ ions for 1Ca2+ ion. The first 20 amino acids of the f-loop, named exchanger inhibitory peptide (XIPNCX1), represent an autoinhibitory region involved in the Na+-dependent inactivation of the exchanger. Previous research has shown that an exogenous peptide having the same amino acid sequence as the XIPNCX1 region exerts an inhibitory effect on NCX activity. In this study, we identified another regulatory peptide, named P1, which corresponds to the 562-688aa region of the exchanger. Patch-clamp analysis revealed that P1 increased the activity of the exchanger, whereas the XIP inhibited it. Furthermore, P1 colocalized with NCX1 thus suggesting a direct binding interaction. In addition, site-directed mutagenesis experiments revealed that the binding and the stimulatory effect of P1 requires a functional XIPNCX1 domain on NCX1 thereby suggesting that P1 increases the exchanger activity by counteracting the action of this autoinhibitory sequence. Taken together, these results open a new strategy for developing peptidomimetic compounds that, by mimicking the functional pharmacophore of P1, might increase NCX1 activity and thus exert a therapeutic action in those diseases in which an increase in NCX1 activity might be helpful.

UR - http://www.scopus.com/inward/record.url?scp=84924081399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924081399&partnerID=8YFLogxK

U2 - 10.1038/mt.2014.231

DO - 10.1038/mt.2014.231

M3 - Article

C2 - 25582710

AN - SCOPUS:84924081399

VL - 23

SP - 465

EP - 476

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 3

ER -